EO4010 in Previously Treated Metastatic Colorectal Carcinoma

Phase 1

Active, not recruiting

• Conditions: Colorectal Cancer Metastatic
• Interventions: Drug: EO4010

• Registration Number: NCT05589597
• Lead Sponsor: Enterome

Brief Summary

Open-label multicenter study

Detailed Description

This is an open-label, multicenter, FIH, phase 1/2 trial to assess safety, tolerability, immunogenicity, and preliminary efficacy of the microbial-derived therapeutic vaccine EO4010 in combination with nivolumab and/or bevacizumab for treatment of patients with unresectable, previously treated, metastatic colorectal cancer

Study Timeline

• Study First Submitted: 2022-10-14
• Study First Submitted QC: 2022-10-18
• Study First Posted: 2022-10-21
• Study Start: 2023-06-01
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-10
• Last Update Posted: 2024-10-14
• Primary Completion: 2026-02
• Study Completion: 2026-02

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

1. Provided written informed consent
2. Histological confirmation of advanced non-resectable colorectal adenocarcinoma
3. Patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for
4. Progression during or within 3 months following the latest administration of standard therapies
5. Age ≥ 18 years old
6. Human leukocyte antigen (HLA)-A2 positive
7. ECOG performance status 0 or 1
8. Measurable disease according to Response Evaluation Criteria in Solid Tumors criteria (RECIST)
9. Patients with a life expectancy of at least 3 months
10. Female patients of childbearing potential must have a negative serum pregnancy test
11. Patients following recommendations for contraception
12. Patients willing and able to comply with the study procedures

Exclusion Criteria

1. Patients treated with dexamethasone > 2 mg/day or equivalent within 14 days before randomization, unless required to treat an adverse event

2. Patients treated with radiotherapy within 12 weeks, and cytotoxic chemotherapy therapy within 28 days

3. Patients with persistent Grade ≥ 2 toxicities (according to NCI-CTCAE v5.0). Toxicities must be resolved for at least 2 weeks to Grade 1 or less

4. Patients who have received any prior treatment with compounds targeting PD1, PDL1, CTLA-4, or similar compounds

5. Patients who have previously received trifluridine/tipiracil (TAS-102) or regorafenib

6. Patients with prior exposure to EO2401, EO2040, or EO4010, i.e. therapeutic vaccine compounds including all or some components of EO4010

7. Patients with the following abnormal laboratory values:

   1. Lymphocyte count decreased, grade 2 (lymphocytes <800 - 500/mm3; <0.8 - 0.5 x 109/L), or worse grade
   2. Hemoglobin < 10 g/dL (6.2 mmol/L); transfusion is acceptable to reach the value
   3. Absolute neutrophil count decrease (<1.5 x109/L)
   4. Platelet count decrease (< 75 ×109/L)
   5. Total bilirubin > 1.5 ×upper limit of normal
   6. Alanine aminotransferase (ALT) > 3 ×ULN; if disease metastatic to the liver > 5 xULN
   7. Aspartate aminotransferase (AST) > 3 ×ULN; if disease metastatic to the liver > 5 xULN
   8. Serum creatinine increase (> 1.5 ×ULN)
   9. Abnormal thyroid function per local laboratory levels

8. Other malignancy or prior malignancy with a disease-free interval of less than 3 years prior to ICF signing; except those treated with surgical intervention and an expected low likelihood of recurrence

9. Patients with clinically significant active infection, cardiac disease, significant medical or psychiatric disease/condition

10. Patients with suspected autoimmune or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g., Guillain-Barré syndrome)

11. Patients with a history of solid organ transplantation or allogeneic hematopoietic stem cell transplantation

12. Patients with a history or known presence of tuberculosis

13. Pregnant and breastfeeding patients

14. Patients with a history or presence of human immunodeficiency virus (HIV) and/or active hepatitis B virus (HBV)/hepatitis C virus (HCV)

15. Uncontrolled central nervous system (CNS) metastasis

16. Patients who have received live or attenuated vaccine therapy used for prevention of infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the first dose of study drug

17. Patients with a history of hypersensitivity to any excipient, or active substance, present in the pharmaceutical forms of applicable study treatments

18. Patients under treatment with immunostimulatory or immunosuppressive medications

19. Patients who have received treatment with any other investigational agent, or participation in another clinical trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Cohort 1	EO4010	E04010 Monotherapy
Cohort 2	EO4010	E04010 in combination with nivolumab
Cohort 3	EO4010	E04010 in combination with nivolumab and/or bevacizumab

Primary Outcome Measures

Name	Time	Method
Safety and tolerability of EO4010 in combination with nivolumab and/or bevacizumab	12months	Incidences of AEs, treatment-emergent AEs (TEAEs), Serious Adverse Events (SAEs), deaths, and laboratory abnormalities using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

Secondary Outcome Measures

Name	Time	Method
Overall response rate	12 months	Defined as the percentage of patients who have a partial or complete response following Response Evaluation Criteria in Solid Tumors criteria
Disease control rate	12 months	Defined as the percentage of patients who have achieved complete response, partial response or stable disease following Response Evaluation Criteria in Solid Tumors criteria
Percentage of patients with shown immunogenicity	12 months	Immunogenicity will be assessed by Interferon-γ ELISpot
Time to response	12 months	Defined as the time interval from first study treatment administration to partial or complete response following Response Evaluation Criteria in Solid Tumors criteria
Duration of response	12 months	Defined as the time interval from first study treatment administration to disease progression or death in patients who achieve complete or partial response following Response Evaluation Criteria in Solid Tumors criteria
Progression free survival	4months	Defined as the time interval from the date of first study treatment administration to the date of progression following Response Evaluation Criteria in Solid Tumors criteria
Overall survival to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up	12 months	Defined as the time interval from the date of first study treatment administration to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up

Trial Locations

Locations (6)

Llavero-Hospital Clínico Universitario; 🇪🇸 Valencia, Spain

MD Anderson; 🇺🇸 Houston, Texas, United States

Hôpital Jean Minjoz; 🇫🇷 Besançon, France

ICM Val d'Aurelle; 🇫🇷 Montpellier, France

Saint Antoine hospital; 🇫🇷 Paris, France

Hospital Universitari Vall d'Hebron; 🇪🇸 Barcelona, Spain